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activating gene deficiencyTo the Editor:
Recombination-activating gene (RAG) deficiency has an
estimated disease incidence of 1:181,000, including severe
combined immunodeficiency (SCID) at a rate of 1:330,000.1,2
Complete or hypomorphic variants of SCID secondary to low re-
combinase activity (<5%) present early with severe infections
and/or clinical signs of systemic inflammation, such as severe
dermatitis, colitis, or both.3,4 Hypomorphic RAG1/2 mutations
with more preserved residual V(D)J recombination activity
(5% to 30%) result in a distinct phenotype of combined immuno-
deficiency with granuloma, autoimmunity, or both.1,2,5 Beyond
combined immunodeficiency, RAG deficiency has been found
in patients with predominantly primary antibody deficiencies6,7
and naive CD41 T-cell lymphopenia in most cases. Currently,
there is no published systematic evaluation for the presence of
an underlying RAG deficiency in patients with primary antibody
deficiencies. There is great variability among diagnostic
modalities for evaluation and treatment for inflammatory lung
disease in case reports of RAG deficiency with no standardized
guidelines. Clinical features and lung disease for patients with
late presentation of RAG deficiency have not been studied exten-
sively. In addition, no studies have examined the prevalence of
RAG deficiency in cohorts of adults with primary immunodefi-
ciency (PID). Here we describe a cohort of 15 patients with
late presentation of RAG deficiency. We also estimate the
prevalence of RAG deficiency in adults with PID after genetic
analysis in 2 separate large cohorts of patients with PID.
We have analyzed the canonical regions of RAG1 and RAG2 in
a total of 692 patients with PID from 2 separate cohorts, one from
the United Kingdom (UK) and one from Austria (Vienna). The
UK cohort is part of the National Institute for Health Research
BioResource–Rare Diseases PID study, as previously described
(Tuijnenburg et al8). In the National Institute for Health Research
BioResource–Rare Diseases PID cohort of 558 patients (299
adults) and the Vienna cohort of 134 patients (106 adults), we
report a total of 5 newly identified cases of RAG deficiency. For
details, see the Methods section and Tables E1 to E3 in this
article’s Online Repository at www.jacionline.org. Based on these
findings, we estimate that the prevalence of RAG deficiency in
adults with PID ranges from 1% to 1.9%. For all adult patients
with PID currently registered with the UK Primary
Immunodeficiency Network database (3294 patients older than
age 18 years), we expect to find an additional 32.9 to 62.6 cases
of RAG deficiency. Gene variants are shown in Fig 1, A. Cohort
demographics are discussed in the Methods section in this
article’s Online Repository.
Functional characterization of novel RAG variants is discussed
in the Methods section in this article’s Online Repository. The
activity of mutant RAG1 and RAG2 proteins normally required
for catalyzingV(D)J recombination events are shown in Table E2.
In addition to the method previously described,9 we also used a 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).system to measure recombination activity in compound
heterozygous cases by means of in vitro expression of murine
RAG1 and RAG2. Both systems simulate the efficiency of protein
expressed in patients in their ability to produce a diverse
repertoire of T-cell receptor and B-cell receptor coding for
immunoglobulins. More than half of the mutant proteins tested
show almost complete loss of activity. All patients tested had an
overall low combined RAG activity (6.4% to 28%).
Immune phenotypes and clinical diagnoses are shown in
Fig 1, B. Persistently low IgG and/or low IgA and IgM levels
are seen in approximately 50% of cases (see Table E3).
Dominant laboratory features were naive CD41 T-cell
lymphopenia with low absolute numbers and fraction of naive
CD41 cells (CD41CD45RA1), and B-cell counts were
variably low (see Table E3). ELISA was used to test for
anti-cytokine antibodies (targeting IFN-a, IFN-v, and
IL-12) on plasma from 7 patients (data not shown). Four
patients had positive results, which is comparable with our
previously reported cohort (56%).5
Most adult RAG-deficient patients had inflammatory
autoimmune complications (87%; see the Methods section
and Fig E1, A, in this article’s Online Repository at
www.jacionline.org). Organ-specific manifestations were
most common (73%) and similar to previously described
reports of 48% to 77%.5,10 Granulomatous disease was seen
in 40% of patients, with 5 of 6 patients showing granuloma
localization within interstitial lung tissue. Other complications
were also seen (see Fig E1, E). Similar to recent reports (21%
to 77%),5,10 cytopenias occurred in 40% of patients: autoim-
mune hemolytic anemia (27%), immune thrombocytopenic
purpura (20%), and autoimmune neutropenia in 1 patient.
Progressive pulmonary diseases were the leading causes of
morbidity and mortality (93%; see Fig E1, D), with pneumonia
being the most common, followed by bronchiectasis, chronic
bronchitis, granuloma, fibrosis, chronic obstructive pulmonary
disease, and bronchiolitis (Fig 1, C). We observed a transition
from acute infectious complications (pneumonia; mean onset,
14 years) to chronic inflammatory complications (mean age,
23 years; Fig 2, A).
Progressive pulmonary diseases were also the leading concern
for successful hematopoietic stem cell transplantation (HSCT).
High-resolution computed tomographic imaging of the lung
revealed bronchiectasis and granuloma. Histology of lung biopsy
specimens (patients 1 and 3) revealed atypical lymphoid
hyperplasia with granulomatous features and giant cell formation
(Fig 2, B). Germinal center formations in patient 3 were
comprised of CD31 T cells and CD201 B cells. Patient 1 had
peribronchial fibrosis (Fig 2, B). Pulmonary lung function data
revealed a median forced vital capacity of 79.55%, diffusing
capacity of the lungs for carbon monoxide of 75%, and FEV1/
forced vital capacity ratio of 78%. We performed a retrospective
analysis of pulmonary function tests over 2 ormore years to assess
the decrease in respiratory function. Two of 4 patients had a
significant decrease, indicating a variable degree of lung function
in adult patients with RAG deficiency (see the Methods section
and Fig E1, G, in this article’s Online Repository).
Thirteen (93%) of 14 patients received first-line immuno-
globulin replacement therapy (see Fig E1, B, and Table E2).
Fifty-seven percent received antibiotic prophylaxis, 21%
received antiviral drugs, and 14% received disease-modifying
FIG 1. Gene variants and phenotypes of adults with RAG deficiency. A, Schematic representation of RAG1
and RAG2 adapted from Notarangelo et al.E19 Variants in this cohort (17 in RAG1 and 8 in RAG2) are shown
in red. Known pathogenic variants reviewed previously are shown as blue dots.E19 B, Phenotypes of
RAG deficiency in 15 patients, including those from the National Institute for Health Research
BioResource–Rare Diseases PID and Vienna cohorts. C, Presentation of lung disease (n 5 15). CID,
Combined immunodeficiency; CID G/AI, combined immunodeficiency with granuloma and/or
autoimmunity; COPD, chronic obstructive pulmonary disease; CVID, common variable immunodeficiency;
ICL, idiopathic CD41 T lymphopenia; SPAD, specific polysaccharide antibody deficiency.
FIG 2. Pulmonary disease. A, Onset of pneumonia, bronchiectasis, and granuloma/fibrosis/chronic
obstructive pulmonary disease (COPD; n 5 15). B, High-resolution computed tomography of patients 3
and 9. Histologic examination of lung biopsy specimens from patient 1 with atypical lymphoid hyperplasia
with granuloma and fibrosis (hematoxylin and eosin).
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HSCT. Comparisons of therapeutic approaches revealed no
statistically significant difference in survival. Three of 8
patients who received only immunoglobulin replacement
therapy were deceased. Among patients undergoing
transplantation, the major mortality cause was infection after
HSCT (see Fig E1, C).
RAG1/2 are the most common defective genes associated
with atypical SCID.10 Patients can survive into adulthood,
and our findings suggest that the prevalence of such cases varies
between 1% and 1.9% in adult PID cohorts. Total and naive
CD41 T-cell lymphopenia,4,10 autoimmunity, and progressive
inflammatory lung disease should all prompt further investiga-
tions for RAG deficiency in adults with PIDs. The relative
absence of RAG deficiency in the pediatric cohort of 216
patients suggests that milder forms of RAG deficiency might
not be diagnosed as readily as a PID in childhood. In the era
of whole-exome sequencing, the spectrum of RAG deficiency
broadens further to include adults with autoimmune and
inflammatory manifestations that can result in progressive
decrease. Systemic analysis of PID-related genes9 and
functional in vitro assays that confirm decreased recombination
activity are essential. Laboratory features of naive CD41 T-cell
lymphopenia and the presence of anti-cytokine antibodies can
further support the diagnosis of partial RAG deficiency. Where
RAG deficiency is confirmed, therapy can be adjusted based on
the mechanistic understanding and might ultimately provide a
targeted strategy for early intervention.
This study was conducted in accordance with the Declaration
of Helsinki. Patients provided written informed consent so that
anonymized data could be included in a scientific publication. All
results presented in this study were obtained as part of the routine
medical care received by the patient.
This study makes use of data generated by the NIHR BioResource–Rare
Disease Consortium. A full list of the consortiummembers who contributed to
the generation of the data is available in this article’s Online Repository at
www.jacionline.org. We thank Professor Christian J. M€uller for providing
pathology specimens and Dr Karl Waibel for providing pulmonary function
testing.
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Mexican American children:
Independent and interactive effectsTo the Editor:
Studies linking proximity to traffic, a surrogate measure of
exposure to traffic-related air pollution (TRAP), with an increased
risk of respiratory conditions in children have producedinconsistent findings. Some studies showed positive associations
of TRAP with asthma and wheezing in children with a family
history of asthma or allergies,1,2 whereas other investigations3,4
found positive associations only in children without parental
history of atopic conditions. In the United States, there is evidence
demonstrating that racial/ethnic minority populations including
Mexican Americans (MAs) are more likely to live near major
roads or reside in neighborhoods with increased traffic and
therefore experience a disproportionate share of air pollution
exposure. However, MAs remain underrepresented in research
on the role of TRAP in the etiology of respiratory disease. In
this study, we tested associations of proximity to traffic with
childhood respiratory outcomes (lifetime asthma, lifetime
wheezing, and current wheezing) and whether these associations
differed by parental history of asthma or allergies, individual-
level sociodemographic characteristics, immigration-related
factors, and environmental stressors.
Details of the research methodology are provided in this
article’s Methods section in the Online Repository at
www.jacionline.org. Briefly, individual-level data were
collected as part of the Study of Asthma in Children of Mexican
Descent, a population-based, cross-sectional study.5 Between
August 2004 and April 2005, the parents of 2023 children
(grades K-8) completed a mailed questionnaire or telephone
interview about respiratory conditions and factors related to
asthma in their children. We geocoded the addresses of all
children using geographic information system software. The
locations of all primary arterials were obtained from the Illinois
Department of Transportation for the year 2004. Proximity to
traffic was examined as a 4-level (0-150 m; 151-250 m;
251-500 m; >500 m) and a binary (0-250 m; >250 m) variable.
The study outcomes include parent report of lifetime asthma,
lifetime wheezing (wheezing or whistling), and current
wheezing (in the last 12 months). The final analysis was based
on data for 1925 children with complete data. The current
analysis was approved by the Institutional Review Board of
the University of Illinois at Chicago.
We performed multilevel logistic regression analyses using
generalized estimating equations to estimate the odds ratio (OR)
for the association of proximity to traffic with respiratory
outcomes. In separate analyses, we examined interactions
between the binary traffic-related exposure variable and potential
moderators. All models accounted for clustering of children
within neighborhoods.
Of the 1925 participants, 6.7%, 17.0%, and 6.0% had lifetime
asthma, lifetime wheezing, and current wheezing, respectively,
and 7.8% had parental history of asthma or allergies. In fully
adjustedmultilevel logistic regression analyses treating proximity
to traffic as a 4-level variable, the odds of lifetime asthma were
greater among children who lived between 0 and 150 m (OR,
2.39; 95% CI, 1.39-4.10) and 151 to 250 m (OR, 2.37; 95% CI,
1.34, 4.19) relative to those who lived more than 500 m from a
primary traffic arterial (Table I). When we examined proximity to
traffic as a binary exposure, the odds of lifetime asthma (OR, 2.21;
95% CI, 1.50-3.25) and lifetime wheezing (OR, 1.52; 95% CI,
1.17-1.97) were significantly higher for children who lived 0 to
250 m compared with those who lived more than 250 m from
primary traffic arterials (Table I).
The associations of proximity to primary traffic arterials with
lifetime asthma and lifetime wheezing, but not current wheezing,
were modified by parental history of asthma or allergies (P for
